AXIM® Biotechnologies received coverage initiation from SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies.
The report, released May 10th, reveals AXIM®’s unique position within the nutraceutical and pharmaceutical spaces, recent news from the company’s product development, and the estimated market value of the cannabis industry.
The cannabis industry has seen remarkable growth in recent years according to the report. Estimated at $7.1 billion in 2016, it is expected to reach $50 billion around 2025. Some industry experts feel it could be even sooner. While there is some apprehension surrounding the pace of legalization in the U.S. under the current administration, SeeThruEquity reminds the reader, “progress towards legalization is likely to have an impact on the valuation and perception of Axim and all cannabis companies; however, the company’s strategy includes a global perspective, legal nutraceuticals, and clinical products – not recreational cannabis.”
It is this focus on the medical benefits of cannabis and cannabinoids by AXIM® Biotechnologies that sets them apart from most cannabis companies. The report further states this, saying, “Axim is seeking to emerge with a distinct position in the cannabis-based biosciences market through its research and development activities and patented delivery systems.”
It is this position within in the industry that SeeThruEquity weighed when they gave AXIM®’s stock, trading over $10.50 at press time, a target price of $17.00. Along with the company’s market position, AXIM®’s past efforts over the last 14 years has set up several important developments in the coming months and years.
AXIM® Biotechnologies owns ten patents, giving the company exclusivity on products and techniques like controlled-release, cannabinoid-based chewing gum and a proprietary cannabinoid extraction and purification method. With these patents, AXIM® has developed twenty trademarks including commercially available cannabinoid-infused products and bath and beauty products and pharmaceutical products intended for a number of medical conditions.
It is these pharmaceutical products that present the greatest opportunity for AXIM®. The company has a number of clinical trials planned in its new drug pipeline, but the biggest news comes from a trio of pharmaceutical developments.
AXIM® Biotechnologies is looking to secure its MedChew® Rx as a novel, patented delivery method for cannabinoids in the treatment of patients with multiple sclerosis (MS).
Formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC) – MedChew® Rx will soon undergo Phase III clinical trials for the relief of pain and spasticity associated with MS. Once approved by the European Medicines Agency (EMA), MedChew Rx™ will be available across the European Union.
AXIM® is also running Phase II clinical trials on its CanChew® Plus cannabinoid chewing gum to determine its potential as a treatment for Irritable Bowel Syndrome (IBS). The company has announced it has completed enrollment of the required 40 patients for its clinical trial and has commenced the start of the research with an anticipated return of the results this spring.
Finally, AXIM® will create a functional dronabinol-based chewing gum similar to Marinol using the company’s intellectual property, including their patent on CBD-based controlled release chewing gum that was recently expanded to include all cannabinoids, including THC. AXIM® will be creating their new drug using dronabinol, an isomer of THC that was originally used to make Marinol. First introduced in the U.S. market in 1985, Marinol remains the only FDA approved cannabis-based drug available in the U.S. Axim®’s dronabinol-based gum is intended as a design improvement over Marinol, addressing both safety and efficiency.
These key developments in the company’s new drug pipeline have placed AXIM® Biotechnologies among the industry’s top companies. Top Wall Street Analysts placed AXIM® among the ten most successful cannabis companies, while Fox Business named the company to their top 5 biotech stocks for 2016. AXIM® stock prices outgained all others on the list by nearly 1500 points, placing them on the top of the list.
With a target price of $17.00, SeeThruEquity is looking for a nearly $7.00 increase over current trading prices, revealing the opportunity for growth in AXIM®’s stock value. Current and planned clinical trials, new product development, and the creation of additional company intellectual property is sure to drive that growth.
You can read the full report HERE.
Discover more about AXIM® Biotechnologies and other Medical Marijuana, Inc. investments and portfolio companies on our news feed.